Actively Managed Equity
Overview: All Strategies
Investor Resources
Indexed Equity
Private Equity
Digital Assets
Invest In The Future Today
Take Advantage Of Market Inefficiencies
Make The World A Better Place
Articles
Podcasts
White Papers
Newsletters
Videos
The Bitcoin Monthly
Big Ideas 2024
Investment Focus
DNA Sequencing
Gene Editing
Gene Therapy
Ag Bio
Targeted Therapeutics
Molecular Diagnostics
Overview
- Type: Active Equity
- Typical # of Holdings: 30-50
- Inception: Oct. 2014
- Portfolio Manager: Catherine Wood
-
Analysts:
Alexandra Urman
Pierce Jamieson
Rong Guo
Strategy Description
This actively managed equity strategy seeks long-term capital growth by investing in the US listed securities, including ADRs, of companies focused on the genomics revolution. Companies within this strategy aim to capture the substantial benefits of new products and services associated with technological and scientific developments in DNA sequencing, gene editing, targeted therapeutics, bioinformatics, and agricultural biology.
Availability
| Strategy | ETF | Managed Account | Mutual Fund |
| ARK Genomic Revolution | In Japan |
The content presented does not constitute investment advice, should not be used as the basis for any investment decision, and does not purport to provide any legal, tax or accounting advice. Certain of the statements contained on this website may be statements of future expectations and other forward-looking statements that are based on ARK’s current views and assumptions, and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Please remember that there are inherent risks involved with investing in the markets, and your investments may be worth more or less than your initial investment upon redemption. There is no guarantee that ARK’s objectives will be achieved. Further, there is no assurance that any strategies, methods, sectors, or any investment programs herein were or will prove to be profitable, or that any investment recommendations or decisions we make in the future will be profitable for any investor or client. Professional money management is not suitable for all investors. For full disclosures, please go to our Terms & Conditions page.